Abstract

This is a single-center phase two trial evaluating the efficacy of Amifostine in patients receiving agressive chemotherapy with the DICEP regimen. Amifostine is an antioxidant drug which has been shown to affect apoptosis and survival of hematopoietic progenitor cells. This drug has been shown to protect renal and neruologic tissue from the effects of chemotherapy and there is substantial data suggesting that it may also lessen the impact of chemotherapy upon hematopoiesis. Many patients with malignancies such as non-Hodgkin's lymphoma, Hodgkin's disease, and breast cancer, who otherwise might benefit from dose-intensive chemotherapy, are not eligible because of a lack of collectible stem cells. This trial will seek to determine whether amifostine can sufficiently protect hematopoietic progenitor and stem cells during high-dose chemotherapy to allow the administration of dose-intensive therapy without peripheral blood or bone marrow stem cells. We seek to accrue 20 patients over a period of 12 months.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000833-25
Application #
6265231
Study Section
Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037

  Publications

Winn, Virginia D; Gormley, Matthew; Fisher, Susan J (2011) The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. Pregnancy Hypertens 1:100-8
Delaney, Joseph A C; Scherzer, Rebecca; Biggs, Mary L et al. (2010) Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 24:2201-9
Pan, Warren W; Li, Jain-Dong; Huang, Shuang et al. (2010) Synergistic activation of NF-{kappa}B by bacterial chemoattractant and TNF{alpha} is mediated by p38 MAPK-dependent RelA acetylation. J Biol Chem 285:34348-54
Huang, XueSong; Chen, Ling-Yu; Doerner, Astrid M et al. (2009) An atypical protein kinase C (PKC zeta) plays a critical role in lipopolysaccharide-activated NF-kappa B in human peripheral blood monocytes and macrophages. J Immunol 182:5810-5
Mukherjee, Sumanta; Chen, Ling-Yu; Papadimos, Thomas J et al. (2009) Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J Biol Chem 284:29391-8
Chen, Ling-Yu; Pan, Zhixing K (2009) Synergistic activation of leukocytes by bacterial chemoattractants: potential drug targets. Endocr Metab Immune Disord Drug Targets 9:361-70
Chen, Ling-Yu; Pan, Warren W; Chen, Miao et al. (2009) Synergistic induction of inflammation by bacterial products lipopolysaccharide and fMLP: an important microbial pathogenic mechanism. J Immunol 182:2518-24
Ito, Tatsuo; Yadav, Neelu; Lee, Jaeho et al. (2009) Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification. BMC Dev Biol 9:47
Price, Richard W; Parham, Robin; Kroll, Jing Lu et al. (2008) Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 13:369-74
Dawson, Arthur; Abel, Susan L; Loving, Richard T et al. (2008) CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 4:538-42

Showing the most recent 10 out of 871 publications